US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Qlife Holding AB – Business Update, First Half of 2026

Qlife Holding AB ("Qlife" or the "Company") is pleased to provide a business update for the first half of 2026. During the period, the Company has continued to advance multiple strategic partnership initiatives across both the pharmaceutical and diagnostics sectors, while maintaining steady progress on its Egoo Health platform and regulatory milestones.· Ongoing feasibility project with a global pharmaceutical company progressing according to plan, with expectations of next-stage agreement following completion of current activities. · Dialogue with pharmaceutical company for novel Egoo

Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, announces that it has entered into a feasibility agreement with a global pharmaceutical company with the objective to evaluate a specific biomarker on Egoo Health related to a therapeutic application. The feasibility agreement is fully funded by the pharma company.The feasibility study represents a first step toward a potential collaboration focused on dedicated R&D and regulatory proceedings and future supply of Egoo Health systems for the targeted application. While the pharmaceutical partner

Bulletin from the Annual General Meeting 2026 of Qlife Holding AB

Qlife Holding AB held its Annual General Meeting on 27 May 2026. At the meeting, the following resolutions were made.The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Income statements and balance sheets as well as distribution of the company's profit or loss The Annual General Meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the fiscal year of 2025. The meeting resolved,

QLIFE HOLDING AB, Interim Report Q1, January - March 2026

Approaching strategic partnershipsThe full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter Financial summary – first quarter 2026 · Revenue in the period amounted to kSEK 21 (110). · EBITDA for the period amounted to kSEK –5,502 (–5,269 ), and net loss kSEK -6,225 (-6,120) · The total cash flow in the first quarter amounted to kSEK 5,387 (-8). · Earnings per share before/after dilution for the quarter amounted to SEK -0.73 (-0.73), calculated on weighted average number of shares in the period. Significant events –

Notice of the 2026 Annual General Meeting of Qlife Holding AB

The shareholders of Qlife Holding AB, company registration number 559224-8040, are hereby invited to attend the Annual General Meeting on 27 May 2026 at 11.00 at the offices of Moll Wendén Advokatbyrå at Stortorget 8 in Malmö.The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Right to attend and registration Those who wish to participate in the meeting must: · be listed as a shareholder in the share register prepared by Euroclear Sweden AB concerning the circumstances as

The ISP leaves notifications under the FDI Act without action in connection with allotment to certain investors in Qlife's rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (“Qlife” or the “Company”) announces that the Swedish Inspectorate of Strategic Products (“ISP”) has decided to leave without action the notifications filed under the Swedish Act (2023:560) on the Screening of

Qlife announces the last day of trading in BTA

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREThe rights issue that was announced by Qlife Holding AB (publ) (“Qlife” or the “Company”) on 22 January 2026, which was approved by an extraordinary general meeting on 26 February 2026 (the “Rights Issue”), has been partially

Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREOn 22 January 2026, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 31.4 million, which was approved by an extraordinary general meeting on 26 February 2026 (the “Rights Issue”). The

Qlife provides business update on clinical progress, partnerships and commercialization initiatives

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today provides a business update covering recent milestones, ongoing progress, and priorities for the coming quarters.Clinical validation and regulatory progress Qlife has continued to strengthen the clinical foundation for the Egoo platform. The Company recently published results from the Birmingham PKU study, demonstrating that Egoo performs reliably in real-life settings. Following this milestone, Qlife has also submitted the Egoo Phe system for regulatory approval. In parallel, Qlife has

The subscription period in Qlife’s rights issue ends on Thursday, 19 March 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREThursday, 19 March 2026, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of approximately SEK 31.4 million (the “Rights Issue”). Please note that some banks and brokers may

Hipro to accelerate Egoo development and regulatory approval in China following strong interest

Qlife Holding AB (“Qlife” or the “Company”) today announces that, following the recently communicated strong interest from hospitals in China in evaluating the Egoo platform, its strategic partner Hipro Biotechnology will accelerate the path towards commercialisation based on its full responsibility for the continued development, local adaptation, regulatory approval of Egoo in China.Under the agreed structure, Hipro will manage product development activities, regulatory submissions, manufacturing, and commercialization in the Chinese market. Qlife will receive a royalty of 20 percent on

The subscription period in Qlife’s rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREToday, 5 March 2026, is the first day of the subscription period in Qlife Holding AB's (“Qlife” or the “Company”) issue of a maximum of 15,679,521 shares with preferential rights for existing shareholders at a subscription price

Qlife publishes information document due to upcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (“Qlife” or the “Company”) publishes an information document regarding the Company's new share issue with preferential rights for existing shareholders of approximately SEK 31.4 million, which was resolved by the

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (publ) (“Qlife” or the “Company”) today announces that Jinderman & Partners AB and JJV Investment Group AB (the “Investors”) have entered into agreements to subscribe for shares if the Company’s rights issue,

Bulletin from Extraordinary General Meeting 2026 of Qlife Holding AB

Qlife Holding AB (the “Company” or “Qlife”) held an Extraordinary General Meeting on 26 February 2026, at which the following resolutions were adopted.Resolution on amendment of the Articles of Association The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to amend the Articles of Association's limits for share capital and number of shares as follows. Current Proposed amended wordingwording§ 4 Share § 4 Share capitalThe share capital shall amount to a minimum ofcapitalThe SEK 2,500,000 and a maximum of SEK 10,000,000.

Qlife launches pharmacy pilot project in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the previously communicated pilot project for blood testing in pharmacies has now been launched. The pilot is being initiated in selected pharmacies in the Nordic region and represents an important step in Qlife’s strategy to expand into decentralized healthcare settings.The pilot is designed to evaluate the integration of Qlife’s and Hipro’s point-of-care testing solutions within the pharmacy environment, including workflow, training, and patient uptake. The objective is to

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (publ) (“Qlife” or the “Company”) today announces changes to the commitment structure in the ongoing rights issue, announced by the Company on 22 January 2026. Guarantor John Bäck has converted his guarantee

QLIFE HOLDING AB, Interim Report Q4, October - December 2025

Positioned for scale in 2026 The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporterFinancial summary – fourth quarter 2025 · On 5. October Qlife extends the Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover. The term and exclusivity of the Letter of Intent have been extended, and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. The other material terms and conditions of the Transaction as previously communicated by

Notice of Extraordinary General Meeting 2026 in Qlife Holding AB

The shareholders of Qlife Holding AB, corporate identity number 559224-8040, are hereby invited to attend an Extraordinary General Meeting on 26 February 2026 at 10:00 a.m. at the offices of Moll Wendén Advokatbyrå at Stortorget 8 in Malmö. Right to participate and registration Anyone wishing to participate in the meeting must: · be listed as a shareholder in the share register produced by Euroclear Sweden AB regarding the situation on the record date, which is 18 February 2026, · register for the meeting no later than 20 February 2026. Registration shall be made by post to

Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the Company has formally submitted its Egoo PHE home‑testing system for regulatory approval to the relevant Notified Body and authorities. This marks a major milestone in Qlife’s mission to make high‑quality, decentralized testing for Phenylalanine (PHE) available for patients living with Phenylketonuria (PKU).The submission follows the recently published clinical trial results from Birmingham Women’s and Children’s NHS Foundation Trust, which demonstrated strong performance in

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREToday, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, subject to the approval of an extraordinary general meeting (the “EGM”), resolved to carry out an issue of 15,679,521 shares with preferential

Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, is preparing a pilot project for blood testing in pharmacies across Denmark, Sweden and the UK. Inspired by the success of the UK’s Pharmacy First program, which has now been in operation for a few years and demonstrated significant benefits for both patients and the healthcare system, Qlife is now executing on its plans to bring its blood testing platforms to the pharmacy sector.Pharmacies are expected to play an increasingly important role in healthcare, with blood testing now paving the way for

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media